Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 145.85 USD 0.4% Market Closed
Market Cap: 351.2B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Johnson & Johnson
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Other Liabilities
$22.1B
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
4%
Bristol-Myers Squibb Co
NYSE:BMY
Other Liabilities
$4.7B
CAGR 3-Years
-14%
CAGR 5-Years
0%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Other Liabilities
$24.7B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
5%
Merck & Co Inc
NYSE:MRK
Other Liabilities
$7.5B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
1%
Zoetis Inc
NYSE:ZTS
Other Liabilities
$675m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Other Liabilities
$7.6B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
6%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
351.1B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
155.23 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Other Liabilities?
Other Liabilities
22.1B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Other Liabilities amounts to 22.1B USD.

What is Johnson & Johnson's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
4%

Over the last year, the Other Liabilities growth was 2%. The average annual Other Liabilities growth rates for Johnson & Johnson have been -7% over the past three years , -5% over the past five years , and 4% over the past ten years .

Back to Top